Agios Pharmaceuticals AGIO Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's other income (expense)?
- Agios Pharmaceuticals (AGIO) reported other income (expense) of $119K in Q1 2026.
- How has Agios Pharmaceuticals's other income (expense) changed year-over-year?
- Agios Pharmaceuticals's other income (expense) decreased by 90.5% year-over-year, from $1.25M to $119K.
- What is the long-term trend for Agios Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's other income (expense) has grown at a -39.3% compound annual growth rate (CAGR), from $14.43M to $1.96M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.